Vistagen Appoints Nick Tressler as Chief Financial Officer
VistaGen Therapeutics, Inc. (VTGN)
Last vistagen therapeutics, inc. earnings: 2/13 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vistagen.com
Company Research
Source: Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025."I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. “I look forward to his contributions to our leadership team and the positive impact he will have throughout our company as we continue building momentum and delivering on our vision.”Mr. Tressler brings over 20 years of financial leadership experience in the life sciences industry guiding companies through pivotal growt
Show less
Read more
Impact Snapshot
Event Time:
VTGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTGN alerts
High impacting VistaGen Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VTGN
News
- Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual MeetingBusiness Wire
- Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026 [Seeking Alpha]Seeking Alpha
- VistaGen Therapeutics (NASDAQ:VTGN) was given a new $12.00 price target on by analysts at Stifel Nicolaus.MarketBeat
- Vistagen Therapeutics Inc (VTGN) Q2 2026 Earnings Call Highlights: Progress in Palisade 3 Trial ... [Yahoo! Finance]Yahoo! Finance
- Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
VTGN
Earnings
- 11/13/25 - Miss
VTGN
Sec Filings
- 12/4/25 - Form 4
- 12/4/25 - Form 3
- 12/3/25 - Form 8-K
- VTGN's page on the SEC website